stable angina pectoris
Cardiovascular · 2017–2018
2decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ranolazine Symptomatic treatment of stable angina pectoris in patients on maximum tolerated doses of beta-blockers or calcium channel blockers where revascularisation is… | Mar 2018 | Recommended | unclear |
| ranolazine Add-on symptomatic treatment of stable angina pectoris in patients with inadequate symptom control despite taking the maximum tolerated dose of a beta-blocker… | Mar 2017 | Not recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.